Teva (NYSE:TEVA) will be responsible for potential commercialization of Uzedy for BP-I. Medincell will be eligible for royalties on net sales. The FDA approved Uzedy for the treatment of ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release injectable suspension for the maintenance treatment of BP-I ...

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug Application for Uzedy extended-release injectable suspension ...

Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd, and Medincell announced that the supplemental New Drug Application (sNDA) for Uzedy extended-release injectable suspension ...

Branded drugs like Austedo and Uzedy face challenges, with Austedo's future revenue potentially affected by IRA negotiations and tepid growth projections for Ajovy and Uzedy. Teva's experimental ...

New data presented by Teva at ECNP 2024* demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris® (RBP-7000) provided the most comparable pharmacokinetic (PK ...

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients with bipolar I disorder. The FDA has accepted a supplemental New Drug ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults in the U.S. The sNDA is based on leveraging ...

This long-acting injectable suspension is proposed for the maintenance treatment of bipolar I disorder (BP-I) in adults. UZEDY is currently approved for use every one or two months as a subcutaneous ...